CLEVELAND, May 31, 2016 /PRNewswire/ -- The Lubrizol Corporation's LifeSciences business has added cGMP sterile powder filling and capsule filling at their Particle Sciences facility.
"In response to client needs, we are expanding our cGMP powder handling capabilities. There has been an uptick in our partners' need for sterile powder filling, both in vials and proprietary devices. To meet this need, we have acquired and qualified the necessary equipment. Powder fills from 50 mg to 75 g, with an accuracy of up to +/- 1% of fill volume, are possible, including those for highly potent compounds," explains Robert W. Lee, Ph.D., vice president of pharmaceutical development services.
As the leading developer of particulates, utilizing both standard and proprietary approaches, the Particle Sciences' facility is supported by full development and analytic services. As previously announced, commercial production at that location will come online in 2017.
"Also included in this latest capability expansion is capsule filling. With a clinical supply capability of 3,000 capsules (sizes 0 – 4) per hour, we are positioned to assist our clients in utilizing our bioavailability-enhancing platforms in oral dosage forms," Lee adds.
Particle Sciences is part of Lubrizol Advanced Materials Inc.
About Particle Sciences
Particle Sciences, part of Lubrizol LifeSciences, is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email email@example.com, or contact us at (610) 861- 4701 for information.
About Lubrizol LifeSciences
Lubrizol LifeSciences links science to life. An in-depth understanding of functional polymer systems, combined with a portfolio of specialty materials, enables LifeSciences to deliver application-specific, quality solutions to the medical device and pharmaceutical industries. The combination of our polymer expertise, drug formulation development and quality contract manufacturing allows LifeSciences to offer our customers end-to-end solutions for success in the drug delivery market.
About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a technology-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It produces and supplies technologies to customers in the global transportation, industrial and consumer markets. These technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care and personal care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions. Our products for the oilfield market include technologies for exploration, production and transportation.
With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 9,000 employees worldwide. Revenues for 2015 were $7 billion. For more information, visit Lubrizol.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/particle-sciences-a-part-of-lubrizol-lifesciences-adds-sterile-powder-filling-and-capsule-filling-capabilities-300277013.html
SOURCE The Lubrizol Corporation